USOO6423719B1 (12) United States Patent (10) Patent No.: US 6,423,719 B1 Lawyer (45) Date of Patent: Jul. 23, 2002 (54) METHOD FOR TREATING BENIGN Hasan et al., “Antagonism of coronary artery relaxation by PROSTATE HYPERPLASA adenosine AA-receptor antagonist ZM241385,” J Cardio vasc Pharmacol. 2000 Feb.; 35(2):322–5. (75) Inventor: Carl H. Lawyer, Mequon, WI (US) Kotera et al., “Immunohistochemical localization of c(GMP binding c(GMP-specific phosphodiesterase (PDE5) in rat (73) Assignee: Upsher-Smith Laboratories, Inc., tissues,” J Histochem Cytochem. 2000 May;48(5):685–93. Minneapolis, MN (US) Landells et al., “The role of adenosine receptors in the action of theophylline on human peripheral blood mononuclear (*) Notice: Subject to any disclaimer, the term of this cells from healthy and asthmatic Subjects.” BrJ Pharmacol, patent is extended or adjusted under 35 2000 Mar.; 129(6):1140–4. U.S.C. 154(b) by 0 days. Lew et al., “Examination of adenosine receptor-mediated relaxation of the pig coronary artery,” Clin Exp Pharmacol (21) Appl. No.: 09/505,220 Physiol, 1999 May–Jun.; 26(5–6):438–43.* Li et al., “Adenosine A receptors increase arterial endot (22) Filed: Feb. 16, 2000 helial cell nitric oxide,” J Surg Res, 1998 Dec.; Related U.S. Application Data 80(2):357-64.* (60) Provisional application No. 60/120,099, filed on Feb. 16, Li et al., “Adenosine enhances nitric oxide production by 1999. vascular endothelial cells,” Am J Physiol, 1995 Aug.; 269(2 Pt 1):C519-23.* (51) Int. Cl. ................................................ A61K 31/52 Olanrewaju et al., “Adenosine A and A receptors in cultured human and porcine coronary artery endothelial (52) U.S. Cl. ............................. 514/263; 514/8; 514/12; cells,” Am J Physiol Heart Circ Physiol, 2000 Aug.; 279(2):H650–6.* 514/15; 514/264; 514/265; 514/922 Rump et al., “Adenosine mediates nitric-oxide-independent renal vasodilation by activation of AA receptors,” J Hyper (58) Field of Search ................................ 514/8, 12, 15, tens. 1999 Dec.; 17(12 Pt. 2):1987–93.* 514/263,264, 265,922 Schmeichel et al., “Methylxanthine bronchodilators poten (56) References Cited tiate multiple human neutrophil functions,” J Immunol. 1987 Mar; 138(6):1896–903.* U.S. PATENT DOCUMENTS Schmidt et al. “The Effect of Selective and Non-selective 2,575,344 A 11/1951 Jones et al. Phosphodiesterase Inhibitors on Allergen- and Leukotriene 4,031,218 A 6/1977 El-Antably C(4)-Induced Contractions in Passively Sensitized Human 4,187,308 A 2/1980 Franzone et al. Airways.” Br J Pharmacol. 2000 Dec.;131(8): 1607–18.* 4,341,783 A 7/1982 Scheindlin ShneyvayS et al., “Induction of apoptosis in cardiac myo 4,581,359 A 4/1986 Ayres cytes by an A. adenosine receptor agonist, Exp Cell ReS. 5,171,217 A 12/1992 March et al. ................. 604/53 1998 Sep.; 243(2):383-97.* 5,753,641 A 5/1998 Gormley et al. ShneyvayS et al., “Induction of apoptosis in rat cardiocytes 5,891,904. A 4/1999 Stief et al. by A. adenosine receptor activation and its Suppression by OTHER PUBLICATIONS isoproterenol.” Exp Cell Res. 2000 May; 257(1):111-26.* Chemical Abstracts 121:50051, “Ocular hypotension (List continued on next page.) induced by topical dopaminergic drugs and phosdiesterase inhibitors” (1994).* Primary Examiner Frederick Krass Kukovetz et al., “Overadditive Synergism Between Theo (74) Attorney, Agent, or Firm- Mueting, Raasch & phylline, Diprophylline and Proxyphylline in Tracheal Gebhardt, PA. Smooth Muscle Relaxation, Arzneimittelforschung, (57) ABSTRACT 33(10): 1450–1454 (1983). Brambilla et al., “Activation of the A. adenosine receptor A method of treating and/or preventing renal dysfunction in affects cell cycle progression and cell growth,” Naunyn a patient, Such as renal colic or contrast nephropathy by Schmiedeberg's Arch Pharmacol, 2OOO Mar.; administering to a patient, a compound of the formula: 361(3):225–34. Brodie et al., “Activation of the AA adenosine receptor O i inhibits nitric oxide production in glial cells,” FEBS Lett. R1 1998 Jun.; 429(1):139–42. NN N Conti et al., “The Molecular Biology of Cyclic Nucleotide Phosphodiesterases,” Prog Nucleic Acid Res Mol Biol. 1. X-R, O N 1999;63:1-38. Conti, "Phosphodiesterases and cyclic nucleotide Signaling R2 in endocrine cells,” Mol Endocrinol. 2OOO Sep.;14(9): 1317-27. Granovsky et al., “Identification of the gamma Subunit-int is described herein. Administration of dyphylline in a Sus eracting residues on photoreceptor cGMP phosphodi tained release oral dosage form is preferred. esterase, PDE6.O., J Biol Chem. 2000 Dec. 29:275(52):41258–62. 21 Claims, No Drawings US 6,423,719 B1 Page 2 OTHER PUBLICATIONS Acara et al., “Probenecid inhibition of the renal excretion of This Week in Science: from Science. Jun. 9, 2000; dyphylline in chicken, rat and man,” J. Pharm. Pharmacol., 288(5472): 1701.* 39(7):526-530 (1987). Walker et al., “Adenosine A receptor activation delayS Becker et al., “The effect of the specific phosphodi apoptosis in human neutrophils,” J Immunol, 1997 Mar.; esterase-IV-inhibitor rollipram on the ureteral peristalsis of 158(6):2926–31.* the rabbit in vitro and in vivo,” J. Urol., 160(3Pt. 1): 920–925 Xu et al., “Atomic Structure of PDE4: Insights into Phos (1998). phodiesterase Mechanism and Specificity,” Science. Jun. 9, Drescher et al., “Alpha-1 receptor mediated Smooth muscle 2000; 288:822-1825.* regulation in benign prostatic hyperplasia,” Scand. J. Urol. Yasui et al., “Effects of theophylline on human eosinophil Nephrol. Suppl., 157:33–40 (1994). functions: comparative Study with neutrophil functions,” J Drescher et al., “Smooth Muscle Contractility in Prostatic Leukoc Biol. 2000 Aug.; 68(2):194–200.* Hyperplasia: Role of Cyclic Adenosine Monophosphate,” Yasui et al., “Theophylline induces neutrophil apoptosis Prostate, 25(2):76–80 (1994). through adenosine A receptor antagonism,” J. Leukoc Biol. 2000 Apr.; 67(4):529–35.* Drescher et al., letter to Editor (regarding “Nephrotoxicity Andersson, “The Concept of Uroselectivity,” Eur: Urol., from contrast media: attenuation with theophylline,” which 33(Suppl. 2):7-11 (1998). appeared in Radiology, 195(1):17-22 (1995)), Radiology, Bang et al., “Cyclic AMP induces transforming growth 197(2):547-548 (1995). factor B2 gene expression and growth arrest in the human Drescher, “Ca" and Cyclic Adenosine Monophosphate androgen-independent prostate carcinoma cell line PC-3.” Involvement in Radiographic Contrast Medium-induced Proc. Natl. Acad. Sci. USA, 89(8):3556-3560 (1992). Renal Vasoconstriction.” J. Vasc. Interv. Radiol, Barza, “Anatomical Barriers for Antimicrobial Agents,” Eur: 6(5):813–818 (1995). J. Clin. Microbiol. Infect. Dis., 12(Suppl. 1):S31-S35 Erley et al., “Adenosine antagonist theophylline prevents the (1993). reduction of glomerular filtration rate after contrast media Boatman et al., “Pharmacological Evaluation of Ureteral application,” Kidney Int., 45(5):1425-1431 (1994). Smooth Muscle, A Technique for Monitoring Ureteral Peri Gladstone et al., “The use of theophylline ethylene diamine stalsis.” Invest. Urol, 4(6):509-520 (1967). (aminophylline) for the relief of biliary collic: a preliminary Coe et al., “The Pathogenesis and Treatment of Kidney report,” J. Am. Med. Assoc., 126(17): 1084-1085 (1944). Stones,” N. Engl. J. Med., 327(16):1141-1152 (1992). Edelstein et al., “Chapter 8: Etiology, Pathogenesis, and Katholiet al., “Nephrotoxicity from Contrast Media: Attenu Management of Renal Failure.” Campbell's Urology, 7" ation with Theophylline,” Radiology, 195(1):17–22 (1995). edition, Walsh et al., eds., W.B. Saunders Co., Philadelphia, King et al., “Purinergic Modulation of Rat Urinary Bladder Title page, publication page, table of contents, and pp. Detrusor Smooth Muscle,” Gen. Pharmacol., 315–341 (1998). 29(4):597–604 (1997). Fair et al., “The pH of Prostatic Fluid: A Reappraisal and Kolonko et al., “The nonselective adenosine antagonist Therapeutic Implications,” J. Urol., 120(6):695-698 (1978). theophylline does prevent renal dysfunction induced by Fang et al., “P-Purinergic Receptor Agonists Inhibit the radiographic contrast agents,” J. Nephrology, 11(3):151-156 Growth of Androgen-independent Prostate Carcinoma (1998). Cells,” J. Clin. Invest., 89(1):191-196 (1992). Lawyer et al., “Utilization of intravenous dihydroxypropyl Kawabe et al., “Use of an O. 1-Blocker, YM617, in the theophylline (dyphylline) in an aminophylline-Sensitive Treatment of Benign Prostatic Hypertrophy,” J. Urol., patient, and its pharmacokinetic comparison with theophyl 144(4):908–912 (1990). Kerttula et al., “Theophylline infusion modulates prostag line,” J. Allergy Clin. Immunol., 65(5):353–357 (1980). landin and leukotriene production in man,” ProStaglandins May et al., “Effect of probenecid on dyphylline elimination,” Leukot. Essent. Fatty Acids, 57(6):555-560 (1997). Clin. Pharmacol Therapeut., 33(6):822–825 (1983). Leoniet al., “the Effects of Isoproterenol and Aminophylline Morcos et al., “Nephrotoxicity from Contrast Media: on Detrusor Muscle Contractility in an Organ Bath Appa Attenuation with Theophylline,” letter to Editor (regarding ratus.” Invest. Urol., 10(6):458–463 (1973). “Nephrotoxicity from contrast media: attenuation with theo Martin et al., “Relationship Between the Effects of Alfuzosin phylline,” which appeared in Radiology, 195(1):17-22 on Rat Urethral and Blood Pressures and its Tissue Con (1995)), Radiology, 197(2):546–547 (1995). centrations,” Life Sci., 63(3):169-176 (1998). Morcos et al., “Contrast Media-induced Nephrotoxicity: A Martin et al., “Functional Uroselectivity.” Eur: Urol., New Insight,” Clin. Radiol., 52(8):573–574 (1997). 33(Suppl. 2):12-18 (1998). Nadai et al., “Pharmacokinetics and the Effect of Probenecid Nolan, “Theophylline option for attenuating contrast medi on the Renal Excretion Mechanism of Diprophylline,” J. a-induced nephrotoxicity in patients on metformin, Am. J. Pharm. Sci., 81 (10): 1024–1027 (1992). Health-Syst. Pharm., 54(5):587–588 (1997). Oesterling, “Benign Prostatic Hyperplasia-Medical and OSSwald et al., “Therapeutic use of theophylline to antago Minimally Invasive Treatment Options,” N.